Remus Pharmaceuticals Ltd.

REMUS

₹1971.65

-0.94% (-18.7)

Market Cap

₹1,162 Cr.

P/E

39.96

About

Remus Pharmaceuticals Limited is a company focusing on the marketing and distribution of finished formulations and API of pharmaceutical drugs. It offers technical consultancy services to distributors… Read more

Remus Pharmaceuticals Limited is a company focusing on the marketing and distribution of finis… Read more

Low

1785

52W Range

High

2835

Timeline

Key company specific updates

Company Timeline

Custom financial statementNew

Edit rows

In Rs. Cr.	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025

In Rs. Cr.	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Balance sheet
Net Block	—	—	—	—	—	—	—	—	11.63	13.66
Shareholders Funds	—	—	—	—	—	—	—	—	86.86	256
Profit & Loss
Operating Profit	—	—	—	—	—	—	—	—	27.81	—
Net Sales	—	—	—	—	—	—	—	—	212	—
Cash flow
Cash from Operating Activity	—	—	—	—	—	—	—	—	3.60	6.99
Net Capex (est)	—	—	—	—	—	—	—	—	0.64	3.68
Ratios
ROCE (%)	—	—	—	—	—	—	—	—	30.21	—
ROE (%)	—	—	—	—	—	—	—	—	24.80	—

Forensics

7 Yes

Positive for this company

3 Neutral

Neutral for this company

5 No

Negative for this company

2 No Data

Insufficient data to analyse

Accounting & Shareholding

Depreciation Effect

Depreciation accounting is not leading to increase in profits
Other Income

Other income is not affecting ratios of the company
Pledge

Promoters have not pledged a significant portion of their holding
Retail Holding

Retail has been selling the stock which is usually a good time to buy
Promoter Holding

Promoter has not sold any shares in the last 90 days
Contingent Liabilities

Company has significant contigent liabilities which can be risky
Revenue Recognition

Chances of aggressive revenue recognition - operating profit of company is not getting converted to cash and recievables rising faster than sales

Price & Performance

ROE

Asset turnover is responsible for roe increase over last 10 years
Debt

Company should not have issues servicing its debt
ROCE Strength

Roce of the company is consistently strong
Capex vs ROCE

Company has made significant capex which might be affecting its roce
Balance Sheet Strength

Balance sheet of the company is strong. but it might have issues paying it suppliers
Share price

Share price has increased over last 10 years but more due to rerating
Working Capital

Company has significant working capital which is dragging its roce and roe
Margin Stability

Margins of the company are volatile
Current vs Historic Valuation

Unable to calculate due to limited data
Sales Growth

Unable to calculate due to limited data

Revenue mix

Product Wise Break-Up

Peer Comparison

Peer Name	Latest Price	PE	Market cap(Cr)	Prom Holding(%)	YoY Qtly Sales(%)	ROCE (%)	ROE (%)
Remus Pharmaceutical	1,971.65	58.38	1,162	70.85	—	30.21	24.8
The Yamuna Syndicate	37,884.4	71.99	1,164	74.87	7.04	1.5	10.48
Credo Brands Mktg	179.71	17.19	1,176	55.06	15.12	18.88	17.33
Uniphos Enterprises	158.36	0.00	1,104	73.79	43.94	1.9	1.86
Oswal Agro Mills	94.59	11.6	1,262	46.89	15,914.47	0.48	0.55
Vasa Denticity	622.55	60.56	1,035	66.5	28.04	28.32	22.06
Manoj Vaibhav Gems	261.68	12.67	1,272	74.27	29.03	22.7	13.1
Creative Newtech	692.8	19.59	1,040	56.6	32.5	29.25	20.43

Corporate Actions

Consolidated BonusDividend

DATE

DETAILS

2024, Nov 19

Dividend Dividend of Rs.1 per share

2024, Jun 06

Bonus 3 bonus shares for every 1 held. Bonus shares should be credited within 3 days after the ex-date.

2024, May 02

Dividend Dividend of Rs.4 per share

2023, Oct 27

Dividend Dividend of Rs.2 per share

2023, Sep 15

Dividend Dividend of Rs.2 per share

FAQs on Remus Pharmaceuticals Ltd. Business

What does Remus Pharmaceutical do?

Remus Pharmaceuticals Limited is involved in marketing, distributing pharmaceutical formulations and APIs. It offers technical consultancy services to distributors and aims to build lasting relationships globally.

Who are the competitors of Remus Pharmaceutical?

Remus Pharmaceutical major competitors are The Yamuna Syndicate, Credo Brands Mktg, Uniphos Enterprises, Oswal Agro Mills, Vasa Denticity, Manoj Vaibhav Gems, Creative Newtech.
Market Cap of Remus Pharmaceutical is ₹1,162 Crs.
While the median market cap of its peers are ₹1,164 Crs.

Is Remus Pharmaceutical financially stable compared to its competitors?

Remus Pharmaceutical seems to be less financially stable compared to its competitors.
Altman Z score of Remus Pharmaceutical is 5.97 and is ranked 5 out of its 8 competitors.

View FAQ's On Shareprice

Promoter Increasing Stake

Promoters buy for just one reason - stock will go up. List of comapnies with them continuosly increasing stake

Run Query

Company Filing

	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010
Annual Report	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12	FY11	FY10
Earnings Release
Investor Presentation
Conference Call
Conference Call SummaryCon Call Summary Powered by Gemini

Discussions & Analysis

[]

Ideas Dashboard

Timeline

Watchlist

Portfolio

Alerts

Research

Stock Screener

Market

Raw Material

Remus Pharmaceuticals Ltd.

Remus Pharmaceuticals Ltd.

About

Timeline

Company Timeline

7 Yes

3 Neutral

5 No

2 No Data

Accounting & Shareholding

Depreciation Effect

Other Income

Pledge

Retail Holding

Promoter Holding

Contingent Liabilities

Revenue Recognition

Price & Performance

ROE

Debt

ROCE Strength

Capex vs ROCE

Balance Sheet Strength

Share price

Working Capital

Margin Stability

Current vs Historic Valuation

Sales Growth

Product Wise Break-Up

UNLOCK PREMIUM

What does Remus Pharmaceutical do?

Who are the competitors of Remus Pharmaceutical?

Is Remus Pharmaceutical financially stable compared to its competitors?

SIGN UP FOR FREE